egs
02-12-2003, 08:47 AM
I just received the following post from the HCV Advocate Listserve:
Update from Three Rivers Pharmaceuticals -
I am happy to update you with some good news from Three Rivers! We have settled our litigation issues with Schering-Plough and we are getting very close to marketing our generic ribavirin.
We are in the final review phase at FDA and hope to launch our product this Spring. Our ribavirin drug product will be marketed as Ribasphere (Ribavirin, USP) 200 mg. Capsules, and we will surely provide the lowest-cost for ribavirin in the market.
Hopefully, this will provide additional assistance with your cause and increase the treatment options for incarcerated individuals. We will surely provide the lowest price to all prisons. Please pass this information along to any of your contacts who may be interested. We are setting up customer
information so that we can begin processing orders as soon as possible.
Christine Sheehy
Three Rivers Pharmaceuticals
312 Commerce Park Drive
Cranberry Township, PA 16066
ph 724-778-6100
fx 724-778-6101
csheehy@3riverspharma.com
__________________________________________________ ____
CRANBERRY TOWNSHIP, Pa., Feb. 7 /PRNewswire/ -- Three Rivers Pharmaceuticals,
LLC today announced that it had reached final settlement with Schering Corporation in the patent litigation case involving the drug ribavirin (REBETOL(R)). Three Rivers is currently seeking approval from the U.S. Food and Drug Administration to manufacture and commercially market a generic form of the drug ribavirin.
Under the terms of the settlement Schering has provided a non-exclusive license to Three Rivers for all its U.S. patents related to this drug product. In return for this license, Three Rivers will pay Schering a reasonable royalty based upon net sales of its generic version of the product. The parties have been in litigation in the U.S. District Court for the Western District of Pennsylvania. The Agreement is subject to the
Court's dismissal of the relevant lawsuits.
Three Rivers is also currently in litigation with Ribapharm, Inc., regarding certain patents that Ribapharm asserts relate to ribavirin. A trial date in that litigation is scheduled for May 2003. Three Rivers does not have tentative approval from the FDA at this time, although the company anticipates an approval within a reasonable period of time. The product will
not be launched until the Ribapharm litigation is satisfactorily resolved and FDA approval obtained.
"We are very pleased with the terms of the settlement. It places Three Rivers one step closer to providing an affordable version of ribavirin to persons afflicted with hepatitis C," said Donald Kerrish, President of Three
Rivers.
REBETOL(R) is indicated for the treatment of chronic hepatitis C and had branded sales of approximately $800 million in the past year.
Three Rivers Pharmaceuticals, LLC, is a privately owned generic drug manufacturing company located in Cranberry Township, Pennsylvania, just north of Pittsburgh.
Update from Three Rivers Pharmaceuticals -
I am happy to update you with some good news from Three Rivers! We have settled our litigation issues with Schering-Plough and we are getting very close to marketing our generic ribavirin.
We are in the final review phase at FDA and hope to launch our product this Spring. Our ribavirin drug product will be marketed as Ribasphere (Ribavirin, USP) 200 mg. Capsules, and we will surely provide the lowest-cost for ribavirin in the market.
Hopefully, this will provide additional assistance with your cause and increase the treatment options for incarcerated individuals. We will surely provide the lowest price to all prisons. Please pass this information along to any of your contacts who may be interested. We are setting up customer
information so that we can begin processing orders as soon as possible.
Christine Sheehy
Three Rivers Pharmaceuticals
312 Commerce Park Drive
Cranberry Township, PA 16066
ph 724-778-6100
fx 724-778-6101
csheehy@3riverspharma.com
__________________________________________________ ____
CRANBERRY TOWNSHIP, Pa., Feb. 7 /PRNewswire/ -- Three Rivers Pharmaceuticals,
LLC today announced that it had reached final settlement with Schering Corporation in the patent litigation case involving the drug ribavirin (REBETOL(R)). Three Rivers is currently seeking approval from the U.S. Food and Drug Administration to manufacture and commercially market a generic form of the drug ribavirin.
Under the terms of the settlement Schering has provided a non-exclusive license to Three Rivers for all its U.S. patents related to this drug product. In return for this license, Three Rivers will pay Schering a reasonable royalty based upon net sales of its generic version of the product. The parties have been in litigation in the U.S. District Court for the Western District of Pennsylvania. The Agreement is subject to the
Court's dismissal of the relevant lawsuits.
Three Rivers is also currently in litigation with Ribapharm, Inc., regarding certain patents that Ribapharm asserts relate to ribavirin. A trial date in that litigation is scheduled for May 2003. Three Rivers does not have tentative approval from the FDA at this time, although the company anticipates an approval within a reasonable period of time. The product will
not be launched until the Ribapharm litigation is satisfactorily resolved and FDA approval obtained.
"We are very pleased with the terms of the settlement. It places Three Rivers one step closer to providing an affordable version of ribavirin to persons afflicted with hepatitis C," said Donald Kerrish, President of Three
Rivers.
REBETOL(R) is indicated for the treatment of chronic hepatitis C and had branded sales of approximately $800 million in the past year.
Three Rivers Pharmaceuticals, LLC, is a privately owned generic drug manufacturing company located in Cranberry Township, Pennsylvania, just north of Pittsburgh.